AmarJGajjarMD

Pediatric Hematology & Oncology • Memphis, TN

Pediatric Neuro-Oncology

Chair/Member, St. Jude Children's Research Hospital

Join to view full profile

Dr. Gajjar is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Gajjar's full profile

Already have an account?

Office
St. Jude Children's Research Hospital
262 Danny Thomas Place
Memphis, TN 38105

Summary

Dr. Amar Gajjar currently serves as Chair of the Department of Pediatric Medicine, Full Member, and co-leader of the Neurobiology and Brain Tumor Program at St. Jude Children’s Research Hospital in Memphis, TN. In 2007, he was named Scott and Tracie Hamilton Endowed Chair in Neuro-Oncology.

He is principal or co-principal investigator of several innovative clinical trials addressing a variety of brain tumors, with special emphasis on medulloblastoma. He has been instrumental in the growth of the Neuro-Oncology Program at St. Jude and developed international collaborations with leading brain tumor programs in Germany, UK, Australia, Canada, and the United States. He has served on the Editorial Board of Neuro-Oncology, Journal of Clinical Oncology, and serves as an ad hoc reviewer for many scientific journals. He has mentored numerous fellows in neuro-oncology who are scattered around the globe.

Incorporating biomarkers into clinical trial design

Dr. Gajjar speaks with ecancer at the Cancer Research UK Brain Tumor Conference in London, 2018.

Education & Training

University of Tennessee/St. Jude Children's Research HospitalFellowship, Department of Hematology/Oncology, Division of Neuro-Oncology, 1989 - 1993
University of South Florida MorsaniChief Residency, Pediatrics, 1988 - 1989
University of South Florida MorsaniResidency, Pediatrics, 1986 - 1988
Grant Medical CollegeClass of 1984
Grant Medical College and Sir JJ Group of HospitalsMBBS, 1982

Certifications & Licensure

TN State Medical License 1989 - 2026
OK State Medical License 1985 - 1991
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2009-2014
Memphis Magazine: Top Doctors Castle Connolly, 2008-2009, 2014
America's Top Doctors for Cancer Castle Connolly, 2006-2013

Clinical Trials

Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma Start of enrollment: 2007 Dec 17
Active, not recruiting
Phase 2
Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors Start of enrollment: 2012 Jun 27
Active, not recruiting
Phase 2
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma Start of enrollment: 2013 Jun 23
Active, not recruiting
Phase 2
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas Start of enrollment: 2013 Sep 03
Completed
Phase 1
Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-metastatic Desmoplastic Medulloblastoma Start of enrollment: 2013 Dec 24
Completed
Phase 2
Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors Start of enrollment: 2014 May 14
Active, not recruiting
Phase 2
Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas Start of enrollment: 2015 Oct 30
Active, not recruiting
Phase 1
Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma Start of enrollment: 2017 Nov 17
Active, not recruiting
Phase 2
Fimepinostat in Treating Brain Tumors in Children and Young Adults Start of enrollment: 2019 Aug 07
Active, not recruiting
Early Phase 1
Roles: Contact
BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas Start of enrollment: 2019 Apr 03
Recruiting
Phase 1
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

1198 citations
Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas
Gang Wu, Alberto Broniscer, Troy A. McEachron, Charles Lu, Barbara S. Paugh
Nature Genetics. 2012-01-29
188 citations
Frequent Amplification of a chr19q13.41 MicroRNA Polycistron in Aggressive Primitive Neuroectodermal Brain Tumors
Meihua Li, Kyle F. Lee, Yuntao Lu, Ian D. Clarke, David Shih
Cancer Cell. 2009-12-08
153 citations
Outcome and prognostic features in pediatric gliomas: a review of 6212 cases from the Surveillance, Epidemiology, and End Results database.
Ibrahim Qaddoumi, Iyad Sultan, Amar Gajjar
Cancer. 2009-12-15

Journal Articles

Association of Hearing Impairment with Neurocognition in Survivors of Childhood Cancer
Daniel A Mulrooney, Amar Gajjar, Alberto S Pappo, JAMA Oncology
Computerized Assessment of Cognitive Impairment Among Children Undergoing Radiation Therapy for Medulloblastoma
Giles W Robinson, Thomas E Merchant, Amar Gajjar, Heather M Conklin, Journal of Neuro-Oncology
Molecular Heterogeneity and CXorf67 Alterations in Posterior Fossa Group A (PFA) Ependymomas
Noah D Sabin, Amar Gajjar, Thomas E Merchant, David W Ellison, Ryan Lee, Paul Klimo, Acta Neuropathologica

Authored Content

Association of Hearing Impairment with Neurocognition in Survivors of Childhood CancerJuly 2020

Press Mentions

St. Jude Research Highlighted at Annual Meeting of the American Society of Clinical OncologyMay 31st, 2022
From Clinical Trials to Cures: A Breakdown of Research at St. JudeMay 23rd, 2022
Intraventricular Methotrexate May Improve Survival for Medulloblastoma SubtypesJuly 17th, 2020
Join now to see all